Introduction {#Sec1}
============

The elderly constitute a significant portion of the acute coronary syndrome (ACS) population, with over 75 year olds representing 27--34 % in European registries \[[@CR1]\]. Furthermore, aging patients are an increasing cohort, with over 85 year olds expected to triple by the year 2035 \[[@CR2]\]. This changing epidemiology presents new difficulties in diagnostic and management strategies. Cardiovascular medicine is a continually evolving and progressive discipline. However, elderly patients are frequently under-represented in clinical trials, leading to uncertainty among clinicians about the relative efficacy and safety of some treatments in this group and, as a consequence, they are less likely to receive evidence-based therapies \[[@CR3]\].

Although at higher baseline risk, this contributes further to the poorer outcomes in elderly patients compared with younger patient groups \[[@CR4]\]. This paper aims to review and summarize the latest evidence and guidelines relevant to managing elderly patients, with discussion of current patterns of practice and the obstacles to delivering guideline-directed care.

This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.

Clinical Characteristics of Elderly Patients with ACS {#Sec2}
=====================================================

Mehta et al. analyzed 163,140 hospital admissions of Medicare beneficiaries age ≥65 admitted from 1994 to 1996 and subcategorized these patients by age \[[@CR5]\]. Increasing age was associated with a greater incidence of functional limitations, heart failure, prior coronary disease, and renal insufficiency \[[@CR5]\]. Conversely, there is less diabetes and fewer male patients in older subgroups \[[@CR5]\].

Through analysis of five nationwide Italian registries, De Luca et al. demonstrated the changing characteristics of the elderly cohort (\>75 years of age) admitted to coronary care units with an acute myocardial infarction over time from 2001 to 2010 \[[@CR6]\]. This showed increased hypertension, renal dysfunction, and previous PCI but reduced history of previous stroke, myocardial infarction, or heart failure compared to earlier cohorts \[[@CR6]\].

Diagnosis and Initial Treatment {#Sec3}
===============================

Recognition of ACS can be difficult in older patient groups. This is due a combination of patient factors with multiple barriers to diagnosis, but also due to inadequacies in service provision. Elderly patient groups are less likely to call emergency services or make their own way to hospital, and patients aged over 65 who do contact emergency services were found to be given a lower priority than patients aged 51--64 years old \[[@CR7], [@CR8]\]. The joint American Colleges of the American Heart Association and American College of Cardiology (AHA/ACC) as well as the European Society of Cardiology (ESC) guidelines state that the initial ECG should be taken within 10 min \[[@CR9], [@CR10]\]. However, the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress ADverse Outcomes with Early Implementation of the ACC/AHA Guidelines) registry highlighted that elderly patients (\>85) on average wait an additional 7 min before receiving an initial ECG, and women over 85 were shown to wait for an average of 45 min \[[@CR4], [@CR11]\].

Diagnosis is further delayed by the atypical presentation of elderly patients as found by the GRACE (Global Registry of Acute Coronary Events) registry \[[@CR12]\]. Atypical symptoms included dyspnea in 49%, diaphoresis in 26 %, nausea or vomiting in 24%, and syncope in 19% (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR12]\]. Other confounders to diagnosis found more frequently in these patients include silent myocardial infarctions, which account for up to 60% of infarcts in patients over 85 years old, and concurrent illnesses such as pneumonia \[[@CR4]\].Fig. 1Elderly patients often present with atypical symptoms other than chest pain

Inequalities in care were also found on admission, with elderly patients less likely to be admitted to a cardiology ward or under the care of a consultant cardiologist \[[@CR13]\]. This is likely multifactorial, due to factors such as delayed diagnosis, atypical presentation, increased resource requirements, and prolonged length of stay.

Given that elderly patients with ACS have poorer outcomes than their younger counterparts, in part due to the difficulties and delays in diagnosis, a high index of suspicion in the elderly population is therefore advised by European guidelines \[[@CR10]\].

Antiplatelets {#Sec4}
=============

Antiplatelet agents as recommended for ACS by AHA/ACC and ESC guidelines are frequently underprescribed in the elderly \[[@CR14]\]. Aspirin gained United States Food and Drug Administration approval for use in primary and secondary prevention of cardiovascular disease in 1985. There are no trials designed to assess the effect of aspirin specifically in elderly patients, and elderly patients are underrepresented in other studies despite the increased risk of coronary heart disease and stroke in this group \[[@CR15]\]. Analyses of previous trials have shown that patients over the age of 65 have a greater absolute risk reduction and a similar relative risk reduction in vascular end points than younger patient cohorts, and a 22% lower 30-day mortality (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR4], [@CR14], [@CR16]\]. Moreover, a similar trend of reduced risk of stroke, myocardial infarction (MI), vascular events, and death was witnessed in the very elderly (\>85 years old) \[[@CR14], [@CR17]\].Fig. 2Medical therapies such as aspirin have an important role in treating many elderly patients

The GRACE registry demonstrated that age is independently linked to an increased bleeding risk in ACS patients. Although many studies have not shown increased bleeding in these groups with pharmacotherapy, this is likely due to patient selection, and concerns remain about bleeding in elderly groups \[[@CR14], [@CR17], [@CR18]\]. This is further discussed in a review paper by Patrono et al., who highlight a marked increase in risk of bleeding complications in patients over the age of 70 and especially in patients with a history of gastrointestinal disturbance \[[@CR15]\]. The review paper concludes that it is difficult to assess whether the possible benefits of aspirin exceed the risks of upper gastrointestinal bleeding in this age group \[[@CR15]\]. However, current AHA/ACC and ESC guidelines recommend the initiation of aspirin in patients with suspected ACS without contraindications and regardless of their age \[[@CR4], [@CR9], [@CR10]\]. The ADAPTABLE trial (Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness) is currently enrolling high-risk patients (previous myocardial infarction or significant coronary disease) to receive lower-dose (81 mg) or higher-dose (325 mg) aspirin with the aim to assess efficacy and bleeding risk in patients, comparing older and younger subgroups \[[@CR19]\].

COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) and CURE (Clopidogrel in Unstable Angina to Prevent Recurrent Events) (mean age 64.2 ± 11.3) have shown that combining aspirin and clopidogrel is significantly more effective in reducing composite cardiovascular death (CV), non-fatal MI (myocardial infarction), or stroke than aspirin alone \[[@CR20], [@CR21]\]. Conversely, the combination of both drugs offers less benefits to elderly patients than in younger NSTE-ACS (non ST elevation myocardial infarction) patients with similar absolute (2.0% vs. 2.2%) and smaller relative (13.1% vs. 28.9%) risk reductions \[[@CR4], [@CR21], [@CR22]\]. An exception is in elderly patients undergoing percutaneous coronary intervention (PCI) with higher risk scores or prior revascularization, where older patients had greater benefit \[[@CR4], [@CR23]\]. CURE showed an increase in the risk of major bleeding with dual therapy vs. aspirin alone (3.7% vs. 2.7% placebo; *P* = 0.001) and a small although nonsignificant 17% increase in the risk of life-threatening bleeding (2.1% vs. 1.8%, *P* = 0.13) \[[@CR21]\]. Some authors suggest the routine use of proton pump inhibitors (PPI), which have been shown to decrease the higher incidence of gastrointestinal bleeding associated with antiplatelets in older patients \[[@CR24]\].

The recent introduction of more potent P2Y12 antiplatelet agents has raised more questions in treating the elderly with NSTE-ACS. Ticagrelor is increasingly used in the general population, but guidelines provide limited input with regards to prescription in elderly patients. PLATO (PLATelet inhibition and patient Outcomes) showed ticagrelor as compared with clopidogrel in patients with acute coronary syndromes (also receiving aspirin) was associated with significantly reduced rates of cardiovascular death, myocardial infarction, or stroke without an increase in overall major bleeding, although also with an increase in non-CABG-related bleeding (Fig. [3](#Fig3){ref-type="fig"}) \[[@CR25]\]. Notably, this trial used PLATO definitions of bleeding, with higher non-CABG major bleeding rates seen when using TIMI definitions \[[@CR26]\]. Additionally, there was a significant excess of fatal intracranial bleeding in the ticagrelor group (11 \[0.1%\] vs. 1 \[0.01%\], *P* = 0.02) and excess stroke with ticagrelor in the STEMI (ST elevation myocardial infarction) population 1.7% vs. 1.0% (hazard ratio, 1.63; 95% CI, 1.07 to 2.48; *P* = 0.02) \[[@CR26], [@CR27]\]. Lindholm et al. found no benefit for patients \>65 undergoing revascularization (interaction *P* \< 0.01 vs. patients \<65 years) \[[@CR28]\].Fig. 3All-cause mortality according to age. **a** Estimated event rate at 12 months, ticagrelor vs clopidogrel. **b** Treatment effect by patient age.*HR* hazard ratio,*CI* confidence interval. Reproduced with permission from \[[@CR29]\]

In a PLATO substudy of elderly patients (\>75 years), while absolute incidences of vascular events and bleeding events were higher in the elderly, there was no significant heterogeneity in the benefit of ticagrelor over clopidogrel between patients ≥75 years (*n* = 2878) vs. \<75 years (*n* = 15744) with respect to reduction in composite cardiovascular death, myocardial infarction, or stroke (interaction *P* = 0.56); myocardial infarction (interaction *P* = 0.33); cardiovascular death (interaction *P* = 0.47); definite stent thrombosis (interaction *P* = 0.81); or all-cause mortality (interaction *P* = 0.76) \[[@CR29]\]. Similarly, there was no significant heterogeneity in the small excess of PLATO-defined non-CABG major bleeding with ticagrelor vs. clopidogrel between patients ≥75 years vs. \<75 years (interaction *P* = 0.98) (Fig. [4](#Fig4){ref-type="fig"}) \[[@CR29]\]. A reduced dose of 60 mg twice daily as an alternative to 90 mg twice daily may be safer in the elderly as suggested by the PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54) trial \[[@CR30]\]. Although dyspnea and ventricular pauses were more frequent overall with ticagrelor, there was no finding of an age-related interaction \[[@CR29]\].Fig. 4Overall non-coronary artery bypass graft-related bleeding according to age. **a** Estimated event rate at 12 months, ticagrelor vs clopidogrel. **b** Treatment effect by age.*HR* hazard ratio,*CI* confidence interval. Reproduced with permission from \[[@CR29]\]

TRITON--TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel--Thrombolysis In Myocardial Infarction 38) compared prasugrel with clopidogrel in patients with ACS who were scheduled to have PCI. Patients ≥75 years old had only a small (6%), nonsignificant reduction in the primary efficacy endpoint offset by an excess of TIMI major bleeding, leading to a nonsignificant net clinical benefit (hazard ratio, 0.99; 95% CI, 0.81 to 1.21; *P* = 0.92) \[[@CR31], [@CR32]\]. The excess of bleeding with prasugrel showed a similar relative but greater absolute increase in the subgroup ≥75 years and in the subgroup \<60 kg (common in the elderly) \[[@CR31], [@CR33]\]. Furthermore, those with a history of stroke or transient ischemic attack (common in elderly groups) demonstrated net harm due to non-CABG-related nonfatal TIMI major bleeding \[[@CR31]\]. Currently, the use of prasugrel in patients ≥75 years of age is generally not recommended, and if undertaken (with caution after a careful individual benefit/risk evaluation by the prescribing physician), a lower maintenance dose of 5 mg should be used; the 10-mg maintenance dose is not recommended \[[@CR10]\]. History of stroke or transient ischemic attack is a contraindication \[[@CR34]\]. Research to investigate the use of a reduced dose of prasugrel includes the secondary analysis of TRILOGY ACS (TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes) and the ongoing Elderly ACS II trial (ClinicalTrials.gov IDNCT01777503) \[[@CR35]\].

Anticoagulation {#Sec5}
===============

Multiple studies have shown that anticoagulation with unfractionated heparin (UFH) or low molecular weight heparin (LMWH) can reduce death or MI in NSTE-ACS \[[@CR4], [@CR36]--[@CR43]\]. However, in elderly patients, there are very limited data on the efficacy and safety compared to younger patient subgroups, as many studies fail to report patient age \[[@CR43]\]. Older age may be linked to higher blood levels of heparin and activated partial thomboplastin time, as well as higher anti-Xa levels with renally excreted LMWH \[[@CR4], [@CR44]\]. LMWH has been found to have a more predictable dose response than UFH, but still may benefit from dose adjustment according to age, body weight, and renal function (the latter two may decline with age) \[[@CR45]\].

The SYNERGY (Superior Yield of the New strategy of Enoxaparin, Revascularization and GlYcoprotein IIb/IIIa inhibitors) trial demonstrated a nonsignificant trend of increased TIMI major and GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) severe bleeding with enoxaparin compared with UFH, but similar rates of death or myocardial infarction in elderly patients \[[@CR46]\]. As a consequence, ESC guidelines suggest reducing the dose adjustment of 1 mg/kg once daily in patients over 75 years old with monitoring of anti-Xa levels \[[@CR10]\]. In comparison, the AHA/ACC recommend 1 mg/kg twice daily with alteration based on individual patient characteristics, including creatinine clearance \[[@CR9]\]. The direct thrombin inhibitor fondaparinux, which achieves a relatively low level of anticoagulation (50% of the anti-Xa level of enoxaparin at standard doses) was found to have a lower bleeding risk but a similar efficacy to enoxaparin in the OASIS 5 (Organization for the Assessment of Strategies for Ischemic Syndromes 5) trial, even with moderate renal impairment \[[@CR47]\]. However, given the relatively low level of anticoagulation, top up with unfractionated heparin is required to reduce the risk of catheter thrombosis if the patient undergoes PCI \[[@CR46]\].

Anticoagulation may also be required for additional reasons such as atrial fibrillation. Atrial fibrillation doubles in prevalence with each decade of age, reaching almost 9% at 80--89 years old \[[@CR48]\]. Unsurprisingly, many patients that present with NSTE-ACS have concurrent atrial fibrillation and therefore warrant consideration for triple therapy (vitamin K antagonist, aspirin, and a P2Y12 receptor inhibitor); however, this is associated with a three- to fourfold increase in major bleeding complications \[[@CR10]\]. It has been demonstrated that oral anticoagulation increases the risk of intracranial hemorrhage with increasing age \[[@CR49]\]. The complication is of particular importance due to its higher mortality rate \[[@CR49]\]. The risk is further increased in patients with hypertension, cerebrovascular disease, and with a higher dosage of anticoagulant \[[@CR49]\].

In patients with atrial fibrillation and a moderate to high risk of stroke, American and European guidelines advocate bleeding risk assessment, consideration of stent type (bare metal vs. drug-eluting stent), and limitation of triple therapy duration accordingly \[[@CR9], [@CR10]\]. The HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score may help in such decision-making and acknowledges the increased bleeding risk with age \[[@CR9]\]. Although some guidelines advocate the use of a narrower therapeutic range (2.0--2.5), this has not been investigated through prospective studies \[[@CR9]\].

Other Therapies {#Sec6}
===============

Adjunctive therapies are often underprescribed in the elderly, including patients with no clear contraindication. This is likely multifactorial, due to concerns about polypharmacy, drug interactions, and a lack of information on the risk benefit of medications in this population.

High-intensity statin therapy is recommended for ACS patients who are not contraindicated by both the ESC and AHA/ACC guidelines \[[@CR4], [@CR50]\]. The PROVE IT (Pravastatin or Atorvastatin Evaluation and Infection Therapy) study showed a 16% reduction in death, MI, stroke, late revascularization or readmission for unstable angina with high-dose atorvastatin compared to pravastatin, with this effect extending to older age groups \[[@CR51]\]. PROSPER (PROspective Study of Pravastatin in the Elderly at Risk) showed a 15% relative and 2.1% absolute risk reduction in death or MI in patients over 70 with high-risk features \[[@CR52]\]. The CARE (Cholesterol And Recurrent Events) and LIPID (Long-term Intervention with Pravastatin in Ischemic Disease) trials also showed a benefit of statin use in patients aged 65--75 with a reduced rate of CAD deaths \[[@CR53], [@CR54]\]. In the very elderly (octogenarian) age group, the value of lipid-lowering therapy can be more contentious since randomized data are relatively scarce and analysis may be confounded by an observational J-shaped association between cholesterol levels and all-cause mortality \[[@CR55]\]. Nevertheless, the latest NICE guidance recommends consideration of statin therapy in those \>85 years to reduce the rate of nonfatal myocardial infarction unless treatment is deemed inappropriate due to comorbidity, polypharmacy, general frailty, or life expectancy \[[@CR56]\]. The effect of angiotensin-converting-enzyme (ACE) inhibitors has also been studied in older patient groups. GISSI 3 (Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico) was a large Italian randomized trial investigating the use of ACE inhibitors in acute MI patients with preserved left ventricular function, and included a large proportion (27%) of elderly patients \[[@CR57]\]. This showed that ACE inhibitors post myocardial infarction reduce combined death, heart failure, and left ventricular systolic function at 6 months \[[@CR57]\].

The subsequent studies SAVE (Salvage and Ventricular Enlargement) and AIRE (Acute Infarction Ramipril Efficacy) have demonstrated reduced long-term mortality in elderly patients over 65 years of age after acute myocardial infarction with reduced left ventricular function \[[@CR58], [@CR59]\]. Krumholz et al. studied the effect of ACE inhibitors in 14,129 post-MI patients aged 65 and older, and found that patients who used ACE inhibitors had a significantly reduced 1-year mortality, with this benefit also significant within the \>80-year-old subgroup \[[@CR60]\].

Angiotensin receptor blockers have also been found to benefit outcome post myocardial infarction in the elderly, albeit with an increased incidence of side effects compared with younger patients \[[@CR61]--[@CR63]\].

Aldosterone antagonists can be more difficult to use in elderly patients, particularly in the setting of reduced renal function. While EPHESUS (Eplerenone Post-acute myocardial infarction Heart failure Efficacy and SUrvival Study) did demonstrate an efficacy benefit in elderly patients with left ventricular dysfunction post MI, there was a samller benefit of treatment than seen in younger patients but a higher risk of side effects, including hyperkalemia \[[@CR61], [@CR64]\].

Conversely, beta blockade has been shown to have a similar beneficial effect in both younger and elderly subgroups, with decreased mortality and re-infarction post MI \[[@CR61], [@CR65]--[@CR67]\]. GUSTO-I and COMMIT showed that patients receiving early intravenous beta blockade had a higher risk of an adverse outcome than oral beta-blocker groups, particularly in elderly STEMI patients who are at risk of hemodynamic instability and heart failure \[[@CR68], [@CR69]\].

The benefits of current guideline-directed medical therapies also extend to nonpharmacological methods.

Cardiac rehabilitation has been shown to improve exercise capacity, diabetic glucose control, autonomic function, behavioral characteristics, quality of life, future hospitalization costs, and major cardiovascular morbidity and mortality. Despite having comparable benefit in both elderly patients and younger groups, few are still referred \[[@CR70]\]. This was further demonstrated by Suaya et al., who found that cardiac rehabilitation was used in only 13.9% of elderly patients (defined as \>65) who survived 30 days after an acute myocardial infarction and 31% of patients after bypass surgery \[[@CR71]\]. Notably, the most powerful predictor of patient participation is physician referral and encouragement \[[@CR72]\]. Patients who decline rehabilitation should be encouraged to exercise for at least 30 min on most days and preferably for 45 min 4--5 times a week \[[@CR72]\].

Several specific considerations must be made for elderly patients when considering cardiac rehabilitation. It is important to assess each individual's physical capability and consider the variations in physiology patients experience with age; for example, elderly patients could benefit from a longer warm-up time \[[@CR73]\]. Moreover, an appropriate cooling-down period is particularly important to prevent hypotension (secondary to a delayed baroreceptor response post exercise) \[[@CR73]\].

Revascularization {#Sec7}
=================

Due to a growing elderly population with a high prevalence of coronary disease, the question of whether to revascularize and the strategy of choice is becoming increasingly relevant. At present, research is limited regarding outcomes of elderly patients receiving revascularization therapies, as many major trials fail to enroll elderly subgroups \[[@CR4], [@CR61]\].

The merits of revascularization have been shown in elderly patients with symptomatic stable ischemic heart disease. TIME (Trial of Invasive versus Medical therapy in Elderly patients with chronic symptomatic coronary artery disease) randomized 305 patients aged 75 and above with chronic angina (despite being treated with two antianginal medications) to revascularization vs. medical therapy only \[[@CR74]\]. Patients in the revascularization group showed symptom relief and improved quality of life, with a reduction in the composite of death/MI/readmission with ACS at 6 months (49% medical vs. 19% revascularization (*P* \< 0.0001) \[[@CR70]\]. The large although observational APPROACH (Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease) registry compared 4-year outcomes among 21,573 patients undergoing diagnostic cardiac catheterization. Those 70--79 years of age and, particularly, those ≥80 years of age showed greater adjusted reductions in death with revascularization compared with medical therapy than in those \<70 years of age \[[@CR75]\].

Furthermore, the benefits of revascularization may extend into elderly subgroups with NSTE-ACS. FRISC II (Fragmin and fast Revascularization during InStability in Coronary artery disease) was a randomized controlled trial comparing initial conservative treatment to an invasive strategy (within 7 days from admission) in patients with NSTE-ACS \[[@CR76]\]. At 6 months, the invasive strategy was associated with a lower rate of death or MI (in patients who were troponin positive or with ST changes); the benefit being sustained out to 5 years \[[@CR76]\]. While FRISC II excluded patients \>75 years old, those aged 65--75 years showed a greater absolute reduction in composite death or MI with an invasive treatment strategy compared with patients \<65 years of age \[[@CR76]\].

The TACTICS-TIMI 18 (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy) trial is frequently quoted in clinical guidelines, as it was one of the first to establish that patients presenting with non ST elevation ACS assigned to an early invasive strategy had a reduction in incidence of the composite of death, MI, or readmission with ACS compared with those treated by a conservative strategy \[[@CR77]\]. Less well known is that the significant reduction in death or MI achieved with an invasive strategy was confined to those ≥65 years of age (8.8% vs. 13.6%; *P* = 0.018), and no significant difference was seen in those \< 65 years of age (6.1% vs. 6.5%; *P* \> 0.2) \[[@CR78]\]. This benefit was even greater in those \>75 years (10.8% vs. 21.6%; *P* = 0.016), albeit with higher major bleeding rates (16.6% vs. 6.5%; *P* = 0.009), likely exacerbated by the protocol-mandated use of glycoprotein IIb/IIIa inhibitor in both arms \[[@CR78]\]. Savonitto et al. investigated 313 patients aged 75 years and over, randomly allocating them to an early aggressive strategy (angiography with revascularization if indicated within 72 h) vs. an initially conservative strategy (angiography and revascularization only for patients with recurrent ischemia) \[[@CR79]\]. The primary endpoint included death, myocardial infarction, disabling stroke, repeat hospital stay for cardiovascular cause, or severe bleeding within 1 year \[[@CR79]\]. The primary endpoint occurred in 27.9% (43) of patients undergoing an early aggressive strategy compared to 34.6% (55) of the initial conservative group (hazard ratio, 0.80; 95% CI, 0.53--1.19; *P* = 0.26) \[[@CR79]\]. There was no significant difference in the rates of mortality, myocardial infarction, and readmission between each group \[[@CR79]\]. Patients with normal troponin levels on admission had no benefit from an early aggressive approach, but those with elevated troponin had a significant 57% reduction in the primary endpoint rate (*P* for interaction: 0.0375) \[[@CR79]\].

Choice of Revascularization Strategy {#Sec8}
------------------------------------

Factors such as morbidity, mortality, and complications should be considered when deciding upon the most appropriate revascularization strategy \[[@CR9], [@CR10]\]. Initial studies of PCI in elderly subgroups demonstrated an increased risk of complications; however, as technology and techniques have improved over time, this risk has decreased, with high numbers of elderly patients undergoing PCI (Fig. [5](#Fig5){ref-type="fig"}) \[[@CR6]\]. Furthermore, elderly PCI is increasingly being performed in patients with multiple comorbidities without a significant change in risk, as demonstrated in the Scottish Coronary Revascularization Register \[[@CR80]\].Fig. 5Choice of revascularization strategy in elderly patients over the past decade from 5 nationwide Italian registries. Reproduced from \[[@CR6]\]

The choice of strategy can be more complex when considering patients with multivessel and left mainstem disease. This finding is more prevalent in elderly populations, who also tend to have higher levels of comorbidity. CABG often achieves complete revascularization but may entail prolonged postoperative recovery in elderly patients, whereas PCI may enable same or next-day discharge, early recovery, and potentially a quicker improvement in quality of life.

The mortality benefits of revascularization strategies have been investigated in multiple observational studies. Weintraub et al. compared CABG versus PCI in patients \>65 years of age with multivessel disease, and found a similar mortality at 1 year but improved survival, reduced stroke, and MI at 4 years for CABG patients \[[@CR81]\].

Dacey et al. undertook a review of 1693 octogenarians (80--89 years) undergoing revascularization for two- or three-vessel disease between 1992 and 2001. CABG (predominantly on pump) was associated with higher in-hospital and 6-month mortality compared to PCI but improved survival from 6 months to 8 years \[[@CR82]\].

In a small observational study, Sheridan et al. found that, even in the very elderly (aged 85 and over), while PCI was associated with improved early survival, CABG was associated with a small improvement in survival by 36 months (66% vs. 63%, *P* \< 0.05), although it was noted that the CABG patients were highly selected: they were without congestive heart failure, pulmonary disease, or peripheral vascular disease \[[@CR83]\]. Appropriate patient selection for CABG is very important, particularly in the elderly. Alexander et al. showed that 30-day mortality post-CABG was markedly higher in elderly patients overall (8.1% vs. 3% in younger patients), whereas elderly patients without significant comorbidity had a 30-day mortality of 4%---approaching that of their younger counterparts \[[@CR84]\].

In an analysis of ten trials, Hlatky et al. suggested that CABG confers a mortality benefit specifically in diabetic patients \>65 years in comparison to PCI \[[@CR85]\]. A systematic review of 66 studies (65 observational) concluded that revascularization could be performed in octogenarians with acceptable short- and long-term outcomes, but definite conclusions could not be drawn regarding survival benefit given the paucity of current data \[[@CR85]\].

Although these studies suggest that elderly patients free from comorbidity have postoperative outcomes approaching those of a younger age group, a more robust method of identifying these patients is required. This could allow a better understanding of the risks and benefits for both the patient and the medical team. Additionally, the risk of postoperative complications may take precedence over mortality risk. Alexander et al. showed that octogenarians have an increased risk of neurological and renal complications (twice the rate of younger patients) \[[@CR84]\]. On reviewing 88,154 patients after CABG (43,369 aged 65--79, 8170 patients over 80 years), Bardakci et al. concluded that although early outcomes of octogenarians are acceptable, there are "strikingly lower discharge to home rates," and that long-term quality of life data in this age group are required \[[@CR86]\].

These studies have suggested several potential benefits of revascularization. However, the majority of evidence is observational and based on selected elderly patients. Evidence for CABG in multivessel disease has so far demonstrated increased long-term freedom from cardiac events and improvement in symptoms. Nevertheless, with increased morbidity and mortality in the postoperative period, a longer recuperation time, and increased risk of long-term cognitive impairment (1 in 5 patients), surgical revascularization may not be an acceptable risk to the individual patient.

Current AHA/ACC guidelines state it is reasonable to choose CABG over PCI in NSTE-ACS patients, particularly in diabetics or in those with complex triple vessel disease, to reduce cardiovascular disease events and readmission and to improve survival (IIa level B) \[[@CR9]\]. ESC guidelines state that the elderly should be considered for an early invasive strategy with the option of revascularization after carefully weighing up the risks and benefits (IIa level B) \[[@CR11]\].

STEMI {#Sec9}
=====

The disadvantages incurred by the elderly with NSTE-ACS are paralleled in elderly STEMI patients by a higher likelihood of delayed or atypical presentation \[[@CR77]\]. In addition, many elderly patients have pre-existing LBBB which may confound patient diagnosis \[[@CR77]\]. Multiple trials regarding oral pharmacotherapy in acute myocardial infarction do not differentiate between STEMI and NSTEMI; this is therefore addressed separately (also refer to Table [1](#Tab1){ref-type="table"}).Table 1Summarizing current evidence and guidelines for elderly ACS patients*ACS* acute coronary syndrome, *ACCF/AHA* American College of Cardiology Foundation/American Heart Foundation, *AHA/ACC* American Heart Association/American Heart Association, *AR* absolute risk, *ARB* angiotensin receptor blocker, *CABG* coronary artery bypass graft, *CAD* coronary artery disease, *CI* confidence interval, *CV* cardiovascular, *CVA* cerebrovascular accident, *ESC* European Cardiac Society, *GDMT* guideline-directed medical therapy, *HR* hazard ratio, *iv* intravenous, *kg* kilograms, *mg* milligrams, *LAD* left anterior descending, *MI* myocardial infarction, *NSTE-ACS* non ST elevation acute coronary syndrome, *OR* odds ratio, *P* *p* value, *PCI* percutaneous coronary intervention, *RCT* randomized controlled trial, *RR* relative risk, *sc* subcutaneous, *STEMI* ST elevation myocardial infarction, *SYNTAX* Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery, *TIA* transient ischemic attack, *TIMI* thrombolysis in myocardial infarction, *UFH* unfractionated heparin

Due to concerns regarding increased hemorrhagic risk, multiple thrombolysis trials excluded elderly patients; however, the survival benefit from reperfusion in STEMI patients found in GUSTO I, ISIS-2, and GISSI studies extended to elderly subgroups \[[@CR87]--[@CR90]\]. Berger et al. showed a benefit in 1-year mortality (but not 30-day survival) in selected thrombolysis patients \[[@CR91]\]. In clinical practice, thrombolysis has often been underutilized in the elderly, likely due to concerns about risk of intracranial hemorrhage and nonhemorrhagic stroke (especially in the very elderly), despite the greater absolute benefit in this population \[[@CR77], [@CR92]\]. Furthermore, the adjunctive administration of pre-hospital enoxaparin at a standard dose was associated with an increased rate of intracranial hemorrhage in elderly patients in the ASSENT-3 (ASsessment of the Safety and Efficacy of a New Thrombolytic) PLUS trial \[[@CR93]\]. The Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment (ExTRACT)---Thrombolysis In Myocardial Infarction (TIMI) 25 trial compared the use of adjunctive enoxaparin to unfractionated heparin in patients receiving thrombolysis \[[@CR94]\]. An alternative regimen of enoxaparin administration was devised for patients aged \>75, and involved omitting the initial loading dose and reducing subsequent subcutaneous doses to 0.75 mg/kg every 12 h (with a maximum dose of 75 mg) \[[@CR94]\]. This trial showed a reduction in the primary endpoint (composite death from any cause or nonfatal recurrent myocardial infarction in the first 30 days after randomization) with enoxaparin compared to unfractionated heparin in all subgroups \[[@CR94]\]. The enoxaparin group experienced a higher rate of TIMI major bleeding (including intracranial hemorrhage) at 30 days \[[@CR94]\]. This reduced dosing regimen is suggested by current ESC guidelines for patients over 75 years old as an adjunct to thrombolysis (i.e., patients selected to be appropriate for lysis and who do not have access to primary PCI within 120 min of first medical contact) \[[@CR95]\]. Current American guidelines state that LMWH should not be used as an alternative to unfractionated heparin in patients over the age of 75 who are receiving fibrinolytics \[[@CR50]\].

In Europe, thrombolysis has largely been superseded by primary PCI, and multiple small trials have reduced death, reinfarction, and CVA in elderly patients with PCI vs. thrombolysis, consistent with results in younger patients \[[@CR88], [@CR91], [@CR96], [@CR97]\]. However, despite the availability of primary PCI, elderly patients with STEMI still experience inequalities in care. The CRUSADE initiative reported that there was no attempt to administer reperfusion therapy in 7.2% of non-contraindicated STEMI patients, with reasons cited including older age, female gender, and comorbidity, and such patients had greater in-hospital mortality \[[@CR98]\]. AHA/ACC guidelines state that age alone should not disqualify a patient from early revascularization. Instead, we should use individual judgment based on comorbidities, functional status, and patient directives \[[@CR47]\].

Conclusion {#Sec10}
==========

Whilst newer guidelines acknowledge the rapidly increasing elderly population and its ensuing challenges, it is difficult to create an all-encompassing guideline for such a varied population. Diversity in patient characteristics such as frailty, baseline function, comorbidity, and cognition presents a unique challenge. Biological and chronological ages can differ, and it is therefore the physician's duty not to base treatment choices on age alone. Furthermore, the term "elderly" can cover a period of several decades from 65 years old on---a period during which there are marked changes in patient physiology.

Underrepresentation in trials has led to a comparative lack of evidence and, although there are increasing efforts to complete phase 4 trials in the elderly population, we are still left with questions about how we should best treat our elderly patients.

American and European guidelines emphasize the importance of considering the individual patient. Efforts to comply with current guidance developed from trials in younger cohorts could lead to maleficence such as bleeding or renal failure, so many physicians omit therapy. Conversely, omission of treatment could likewise harm a patient who may otherwise benefit.

Efforts must be made to improve vigilance and recognition of atypical presentation in elderly patients. It is important to collect accurate information promptly which can then be used to judge each patient's suitability for treatment, and not to bias our decisions based on age alone. Furthermore, it is imperative that we facilitate an informed decision-making process for the patient, adapting the information we convey to the individual.

Guideline-directed medical therapy should be considered in the context of the individual patient, with clear reasons for proceeding with (benefits exceed risks) or omitting (risks exceed benefits) treatment. The final decision should be based on current evidence, physician judgment, and patient preference.

No funding or sponsorship was received for this study or publication of this article. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.

Conflict of interest {#d30e1103}
====================

Claire McCune and Peter McKavanagh declare they have no conflicts of interest. Ian Menown has received grants to institution, honoraria, and/or conference sponsorship from Boston Scientific, Sanofi Aventis, Biosensors, Meril Life, OrbusNeich, Menarini, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Lilly, Bristol--Myers Squibb, and Pfizer.

Compliance with ethics guidelines {#d30e1108}
=================================

This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.

Open Access {#d30e1113}
===========

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
